Results of two trials of immunotherapy for patients with severe influenza have surprised researchers by drawing a blank for influenza A, while providing some hope for treatment of influenza B.

The double-blinded trials, published simultaneously in the Lancet Respiratory Medicine, are the first major studies testing the efficacy of an intervention based on the convalescent plasma treatment used in the deadly 1918 flu pandemic.